SCHEMBL2675909

SCHEMBL2675909

O=C(O)c1c(CN2CCN(CCN3CCOCC3)CC2)n(-c2ccc(Cl)cc2)c(=O)c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 3/20 0.52
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTR7 P34969 4/20 0.44
NPSR1 Q6W5P4 3/20 0.44
TSHR P16473 2/20 0.44
ALDH1A1 P00352 4/20 0.42
HTR1A P08908 3/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
KCNH2 Q12809 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
AKR1C3 P42330 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676679 0.93 NPSR1 (0.50) ABCB1HTR7NPSR1TSHRALDH1A1
SCHEMBL2675748 0.92 USP14 (0.45) ABCB1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2677415 0.91 USP14 (0.47) ABCB1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2675259 0.90 ALDH1A1 (0.46) ABCB1HTR7NPSR1TSHRALDH1A1
SCHEMBL2676725 0.90 HTR3A (0.47) ABCB1HTR7NPSR1TSHRALDH1A1
SCHEMBL2675563 0.90 NPSR1 (0.48) ABCB1HTR7NPSR1TSHRALDH1A1
SCHEMBL2676684 0.89 NPSR1 (0.53) CYP2D6CYP2C9CYP2C19NPSR1TSHR
SCHEMBL2676889 0.89 DRD4 (0.51) HTR7ALDH1A1HTR1AMAPTKMT2A
SCHEMBL2677649 0.88 HTR7 (0.45) ABCB1HTR7KCNH2KMT2AMEN1
SCHEMBL2675911 0.87 CNR1 (0.48) HTR7NPSR1TSHRALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ABCB1 476/4885CYP3A4 1071/4885CYP2D6 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.